Global Diabetes Drug Market growth is driven by the rising incidence of diabetes and increasing adoption of innovative treatment solutions.Austin, United States, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ...

Report with market evolution powered by AI - The global antibiotics market size is estimated to grow by USD 18.22 billion ...

An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and ...

Bone-chilling temperatures couldn’t keep the crowds away from Takeda’s Kendall Square campus on Tuesday to celebrate a milestone for the Japanese drugmaker’s new R&D tower. More than 250 ...

Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), (OTCPK:AAPGV) which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering. In an SEC filing ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. “There's an evolution of our economic model that starts with [the] IRA (Inflation ...

Ascentage, backed by Japan's biggest drugmaker Takeda Pharmaceutical (4502.T), opens new tab, is looking to raise $149 million by offering about 7.3 million American depositary shares at $20.34 each.

MONONGAHELA, Pa. (KDKA) - A family in the Mon Valley is sounding the alarm after they said their local hospital failed them. Amanda Rimsek said her dad was experiencing stroke symptoms but claims ...

Later during the conference, Takeda CEO Christophe Weber laid out the company's top pipeline prospects, a group of 6 drugs that could collectively generate $20 billion at peak. And Samsung ...

Takeda has opened an innovation capability centre (ICC) in Bengaluru to leverage the local tech talent pool for building core digital skills. This new centre, part of their Data, Digital ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...